SidaGhanaV1, Ncbi, Merge, bibRecord, 000A37

Screening and diagnosis of HBV in low-income and middle-income countries.

Identifieur interne : 000A37 ( Ncbi/Merge ); précédent : 000A36; suivant : 000A38

Screening and diagnosis of HBV in low-income and middle-income countries.

Auteurs : Jean-Pierre Allain [Royaume-Uni] ; Ohene Opare-Sem [Ghana]

Source :

Nature reviews. Gastroenterology & hepatology [ 1759-5053 ] ; 2016.

RBID : pubmed:27625189

Descripteurs français

KwdFr :
- ADN viral (isolement et purification), Activation virale (physiologie), Anticorps antiviraux (métabolisme), Antigènes de surface du virus de l'hépatite B (métabolisme), Antigènes e du virus de l'hépatite virale B (métabolisme), Antiviraux (usage thérapeutique), Cirrhose du foie (diagnostic), Cirrhose du foie (psychologie), Cirrhose du foie (virologie), Co-infection (), Co-infection (diagnostic), Diagnostic précoce, Dépistage systématique (), Humains, Hépatite B chronique (), Hépatite B chronique (diagnostic), Hépatite B chronique (traitement médicamenteux), Infections à VIH (), Infections à VIH (diagnostic), Marqueurs biologiques (métabolisme), Pays en voie de développement, Production d'anticorps (physiologie), Résistance virale aux médicaments, Virus de l'hépatite B (immunologie).
MESH :
- diagnostic : Cirrhose du foie, Co-infection, Hépatite B chronique, Infections à VIH.
- immunologie : Virus de l'hépatite B.
- isolement et purification : ADN viral.
- métabolisme : Anticorps antiviraux, Antigènes de surface du virus de l'hépatite B, Antigènes e du virus de l'hépatite virale B, Marqueurs biologiques.
- physiologie : Activation virale, Production d'anticorps.
- psychologie : Cirrhose du foie.
- traitement médicamenteux : Hépatite B chronique.
- usage thérapeutique : Antiviraux.
- virologie : Cirrhose du foie.
- Co-infection, Diagnostic précoce, Dépistage systématique, Humains, Hépatite B chronique, Infections à VIH, Pays en voie de développement, Résistance virale aux médicaments.

English descriptors

KwdEn :
- Antibodies, Viral (metabolism), Antibody Formation (physiology), Antiviral Agents (therapeutic use), Biomarkers (metabolism), Coinfection (complications), Coinfection (diagnosis), DNA, Viral (isolation & purification), Developing Countries, Drug Resistance, Viral, Early Diagnosis, HIV Infections (complications), HIV Infections (diagnosis), Hepatitis B Surface Antigens (metabolism), Hepatitis B e Antigens (metabolism), Hepatitis B virus (immunology), Hepatitis B, Chronic (complications), Hepatitis B, Chronic (diagnosis), Hepatitis B, Chronic (drug therapy), Humans, Liver Cirrhosis (diagnosis), Liver Cirrhosis (psychology), Liver Cirrhosis (virology), Mass Screening (methods), Virus Activation (physiology).
MESH :
- chemical , isolation & purification : DNA, Viral.
- chemical , metabolism : Antibodies, Viral, Biomarkers, Hepatitis B Surface Antigens, Hepatitis B e Antigens.
- complications : Coinfection, HIV Infections, Hepatitis B, Chronic.
- diagnosis : Coinfection, HIV Infections, Hepatitis B, Chronic, Liver Cirrhosis.
- drug therapy : Hepatitis B, Chronic.
- immunology : Hepatitis B virus.
- methods : Mass Screening.
- physiology : Antibody Formation, Virus Activation.
- psychology : Liver Cirrhosis.
- chemical , therapeutic use : Antiviral Agents.
- virology : Liver Cirrhosis.
- Developing Countries, Drug Resistance, Viral, Early Diagnosis, Humans.

Abstract

HBV testing and diagnosis of HBV-related liver disease in low-income and middle-income countries differs substantially from that in developed countries in terms of access to resources and expensive technologies requiring highly specialized staff. For identification and classification of HBV infection, genomic amplification methods to detect and quantify HBV DNA are often nonexistent or available only in central laboratories of major cities. When samples from peripheral locations do arrive, delays in receiving results generate loss to follow-up. Testing is often limited to measurement of hepatitis B surface antigen (HBsAg), alanine aminotransferase levels, aspartate aminotransferase to platelet ratio index and hepatitis B e antigen (HBeAg) to determine indications for antiviral therapy (AVT). Utilization of AVT is limited by cost and availability, particularly when patients are not covered by health insurance. The natural history of HBV infection is influenced by genotypes B and C in East Asia, where decades of immune tolerance have led to mostly vertical transmission; in sub-Saharan Africa, where genotypes A1 and E predominate, infection is transmitted horizontally between young children, followed by a nonreplicative phase. In both regions, cirrhosis and hepatocellular carcinoma are common and would be considerably ameliorated by AVT. Implementation of the HBV vaccine since the 1990s in Asia and 2000s in Africa has decreased the incidence of HBV, but vaccine failure and insufficiently effective prevention remain concerning issues.

DOI: 10.1038/nrgastro.2016.138
PubMed: 27625189

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000908
to stream PubMed, to step Curation: 000907
to stream PubMed, to step Checkpoint: 000907

Links to Exploration step

pubmed:27625189

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Screening and diagnosis of HBV in low-income and middle-income countries.</title>
<author><name sortKey="Allain, Jean Pierre" sort="Allain, Jean Pierre" uniqKey="Allain J" first="Jean-Pierre" last="Allain">Jean-Pierre Allain</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Haematology, University of Cambridge, Science Village, Chesterford Research Park, Little Chesterford CB10 1XL, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Haematology, University of Cambridge, Science Village, Chesterford Research Park, Little Chesterford CB10 1XL</wicri:regionArea>
<orgName type="university">Université de Cambridge</orgName>
<placeName><settlement type="city">Cambridge</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Angleterre de l'Est</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Opare Sem, Ohene" sort="Opare Sem, Ohene" uniqKey="Opare Sem O" first="Ohene" last="Opare-Sem">Ohene Opare-Sem</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Department of Medicine, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi</wicri:regionArea>
<wicri:noRegion>Kumasi</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27625189</idno>
<idno type="pmid">27625189</idno>
<idno type="doi">10.1038/nrgastro.2016.138</idno>
<idno type="wicri:Area/PubMed/Corpus">000908</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000908</idno>
<idno type="wicri:Area/PubMed/Curation">000907</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000907</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000907</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000907</idno>
<idno type="wicri:Area/Ncbi/Merge">000A37</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Screening and diagnosis of HBV in low-income and middle-income countries.</title>
<author><name sortKey="Allain, Jean Pierre" sort="Allain, Jean Pierre" uniqKey="Allain J" first="Jean-Pierre" last="Allain">Jean-Pierre Allain</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Haematology, University of Cambridge, Science Village, Chesterford Research Park, Little Chesterford CB10 1XL, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Haematology, University of Cambridge, Science Village, Chesterford Research Park, Little Chesterford CB10 1XL</wicri:regionArea>
<orgName type="university">Université de Cambridge</orgName>
<placeName><settlement type="city">Cambridge</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Angleterre de l'Est</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Opare Sem, Ohene" sort="Opare Sem, Ohene" uniqKey="Opare Sem O" first="Ohene" last="Opare-Sem">Ohene Opare-Sem</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Department of Medicine, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi</wicri:regionArea>
<wicri:noRegion>Kumasi</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature reviews. Gastroenterology & hepatology</title>
<idno type="eISSN">1759-5053</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (metabolism)</term>
<term>Antibody Formation (physiology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Biomarkers (metabolism)</term>
<term>Coinfection (complications)</term>
<term>Coinfection (diagnosis)</term>
<term>DNA, Viral (isolation & purification)</term>
<term>Developing Countries</term>
<term>Drug Resistance, Viral</term>
<term>Early Diagnosis</term>
<term>HIV Infections (complications)</term>
<term>HIV Infections (diagnosis)</term>
<term>Hepatitis B Surface Antigens (metabolism)</term>
<term>Hepatitis B e Antigens (metabolism)</term>
<term>Hepatitis B virus (immunology)</term>
<term>Hepatitis B, Chronic (complications)</term>
<term>Hepatitis B, Chronic (diagnosis)</term>
<term>Hepatitis B, Chronic (drug therapy)</term>
<term>Humans</term>
<term>Liver Cirrhosis (diagnosis)</term>
<term>Liver Cirrhosis (psychology)</term>
<term>Liver Cirrhosis (virology)</term>
<term>Mass Screening (methods)</term>
<term>Virus Activation (physiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (isolement et purification)</term>
<term>Activation virale (physiologie)</term>
<term>Anticorps antiviraux (métabolisme)</term>
<term>Antigènes de surface du virus de l'hépatite B (métabolisme)</term>
<term>Antigènes e du virus de l'hépatite virale B (métabolisme)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Cirrhose du foie (diagnostic)</term>
<term>Cirrhose du foie (psychologie)</term>
<term>Cirrhose du foie (virologie)</term>
<term>Co-infection ()</term>
<term>Co-infection (diagnostic)</term>
<term>Diagnostic précoce</term>
<term>Dépistage systématique ()</term>
<term>Humains</term>
<term>Hépatite B chronique ()</term>
<term>Hépatite B chronique (diagnostic)</term>
<term>Hépatite B chronique (traitement médicamenteux)</term>
<term>Infections à VIH ()</term>
<term>Infections à VIH (diagnostic)</term>
<term>Marqueurs biologiques (métabolisme)</term>
<term>Pays en voie de développement</term>
<term>Production d'anticorps (physiologie)</term>
<term>Résistance virale aux médicaments</term>
<term>Virus de l'hépatite B (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>DNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antibodies, Viral</term>
<term>Biomarkers</term>
<term>Hepatitis B Surface Antigens</term>
<term>Hepatitis B e Antigens</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coinfection</term>
<term>HIV Infections</term>
<term>Hepatitis B, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coinfection</term>
<term>HIV Infections</term>
<term>Hepatitis B, Chronic</term>
<term>Liver Cirrhosis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Cirrhose du foie</term>
<term>Co-infection</term>
<term>Hépatite B chronique</term>
<term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis B, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus de l'hépatite B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hepatitis B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>ADN viral</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Mass Screening</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Antigènes de surface du virus de l'hépatite B</term>
<term>Antigènes e du virus de l'hépatite virale B</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Activation virale</term>
<term>Production d'anticorps</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Antibody Formation</term>
<term>Virus Activation</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Cirrhose du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Liver Cirrhosis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite B chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cirrhose du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Liver Cirrhosis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Developing Countries</term>
<term>Drug Resistance, Viral</term>
<term>Early Diagnosis</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Co-infection</term>
<term>Diagnostic précoce</term>
<term>Dépistage systématique</term>
<term>Humains</term>
<term>Hépatite B chronique</term>
<term>Infections à VIH</term>
<term>Pays en voie de développement</term>
<term>Résistance virale aux médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">HBV testing and diagnosis of HBV-related liver disease in low-income and middle-income countries differs substantially from that in developed countries in terms of access to resources and expensive technologies requiring highly specialized staff. For identification and classification of HBV infection, genomic amplification methods to detect and quantify HBV DNA are often nonexistent or available only in central laboratories of major cities. When samples from peripheral locations do arrive, delays in receiving results generate loss to follow-up. Testing is often limited to measurement of hepatitis B surface antigen (HBsAg), alanine aminotransferase levels, aspartate aminotransferase to platelet ratio index and hepatitis B e antigen (HBeAg) to determine indications for antiviral therapy (AVT). Utilization of AVT is limited by cost and availability, particularly when patients are not covered by health insurance. The natural history of HBV infection is influenced by genotypes B and C in East Asia, where decades of immune tolerance have led to mostly vertical transmission; in sub-Saharan Africa, where genotypes A1 and E predominate, infection is transmitted horizontally between young children, followed by a nonreplicative phase. In both regions, cirrhosis and hepatocellular carcinoma are common and would be considerably ameliorated by AVT. Implementation of the HBV vaccine since the 1990s in Asia and 2000s in Africa has decreased the incidence of HBV, but vaccine failure and insufficiently effective prevention remain concerning issues.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27625189</PMID>
<DateCreated><Year>2016</Year>
<Month>09</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>05</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>05</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-5053</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>11</Issue>
<PubDate><Year>2016</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Gastroenterology & hepatology</Title>
<ISOAbbreviation>Nat Rev Gastroenterol Hepatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Screening and diagnosis of HBV in low-income and middle-income countries.</ArticleTitle>
<Pagination><MedlinePgn>643-653</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrgastro.2016.138</ELocationID>
<Abstract><AbstractText>HBV testing and diagnosis of HBV-related liver disease in low-income and middle-income countries differs substantially from that in developed countries in terms of access to resources and expensive technologies requiring highly specialized staff. For identification and classification of HBV infection, genomic amplification methods to detect and quantify HBV DNA are often nonexistent or available only in central laboratories of major cities. When samples from peripheral locations do arrive, delays in receiving results generate loss to follow-up. Testing is often limited to measurement of hepatitis B surface antigen (HBsAg), alanine aminotransferase levels, aspartate aminotransferase to platelet ratio index and hepatitis B e antigen (HBeAg) to determine indications for antiviral therapy (AVT). Utilization of AVT is limited by cost and availability, particularly when patients are not covered by health insurance. The natural history of HBV infection is influenced by genotypes B and C in East Asia, where decades of immune tolerance have led to mostly vertical transmission; in sub-Saharan Africa, where genotypes A1 and E predominate, infection is transmitted horizontally between young children, followed by a nonreplicative phase. In both regions, cirrhosis and hepatocellular carcinoma are common and would be considerably ameliorated by AVT. Implementation of the HBV vaccine since the 1990s in Asia and 2000s in Africa has decreased the incidence of HBV, but vaccine failure and insufficiently effective prevention remain concerning issues.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allain</LastName>
<ForeName>Jean-Pierre</ForeName>
<Initials>JP</Initials>
<AffiliationInfo><Affiliation>Department of Haematology, University of Cambridge, Science Village, Chesterford Research Park, Little Chesterford CB10 1XL, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Opare-Sem</LastName>
<ForeName>Ohene</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi, Ghana.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>09</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nat Rev Gastroenterol Hepatol</MedlineTA>
<NlmUniqueID>101500079</NlmUniqueID>
<ISSNLinking>1759-5045</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006513">Hepatitis B e Antigens</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Gastroenterol Hepatol. 2014 Dec;12(12):2106-12.e1</RefSource>
<PMID Version="1">24929235</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2005 Nov;12(6):642-7</RefSource>
<PMID Version="1">16255766</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2001 Oct;34(4 Pt 1):617-24</RefSource>
<PMID Version="1">11584355</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2011 Mar 1;52(5):624-32</RefSource>
<PMID Version="1">21245155</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2011 Jan;49(1):298-306</RefSource>
<PMID Version="1">21048009</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2009 Jan;29 Suppl 1:100-7</RefSource>
<PMID Version="1">19207972</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2016 Jan;36 Suppl 1:93-9</RefSource>
<PMID Version="1">26725904</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2009 Mar;81(3):406-12</RefSource>
<PMID Version="1">19152393</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Jun 19;21(10):1323-31</RefSource>
<PMID Version="1">17545709</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Natl Med J India. 2012 Jul-Aug;25(4):207-9</RefSource>
<PMID Version="1">23278777</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2016 Aug;65(8):1369-76</RefSource>
<PMID Version="1">26109530</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Gynaecol Obstet. 2015 Jun;130 Suppl 1:S70-2</RefSource>
<PMID Version="1">25968489</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Gastroenterol. 2015 Jun 7;21(21):6684-97</RefSource>
<PMID Version="1">26074707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vox Sang. 2010 Apr;98(3 Pt 2):403-14</RefSource>
<PMID Version="1">20412171</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood Transfus. 2015 Jul;13(3):401-10</RefSource>
<PMID Version="1">26192780</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2011 Dec;51(12):2588-95</RefSource>
<PMID Version="1">21682731</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2015 Sep;55(9):2272-81</RefSource>
<PMID Version="1">26177670</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2016 Jan;16(1):80-6</RefSource>
<PMID Version="1">26268687</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gen Virol. 2007 Oct;88(Pt 10):2686-95</RefSource>
<PMID Version="1">17872520</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2014 Jul;34(6):e144-50</RefSource>
<PMID Version="1">24502524</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2016 Dec;65(12 ):2007-2016</RefSource>
<PMID Version="1">26185161</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2013 Oct;32(10):1110-5</RefSource>
<PMID Version="1">23694839</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2010 Aug;82(8):1334-40</RefSource>
<PMID Version="1">20572076</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2009 Feb;50(2):227-42</RefSource>
<PMID Version="1">19054588</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Iran Red Crescent Med J. 2011 Dec;13(12):855-62</RefSource>
<PMID Version="1">22737429</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Pathol. 2011 Oct;64(10):916-20</RefSource>
<PMID Version="1">21670074</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gen Virol. 2009 Oct;90(Pt 10):2442-51</RefSource>
<PMID Version="1">19535503</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Trop Pediatr. 2015 Dec;61(6):464-7</RefSource>
<PMID Version="1">26338421</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2009 Jan;16(1):36-44</RefSource>
<PMID Version="1">18673426</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol Methods. 2007 Dec;146(1-2):274-80</RefSource>
<PMID Version="1">17707918</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vox Sang. 2014 Jul;107(1):19-25</RefSource>
<PMID Version="1">24697276</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2015 Mar 10;33(11):1393-9</RefSource>
<PMID Version="1">25595868</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Indian J Med Res. 2010 Sep;132:312-7</RefSource>
<PMID Version="1">20847378</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2015 May 28;33(23):2704-9</RefSource>
<PMID Version="1">25843269</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Liver Dis. 2010 Aug;14(3):425-38</RefSource>
<PMID Version="1">20638023</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Gastroenterol. 2012 Sep;107(9):1306-13</RefSource>
<PMID Version="1">22641308</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Gastroenterol. 2015 Jul 7;21(25):7842-50</RefSource>
<PMID Version="1">26167084</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Gastroenterol. 2009 Jul;104(7):1693-9</RefSource>
<PMID Version="1">19455130</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2009 Jun;49(6):1115-25</RefSource>
<PMID Version="1">19309474</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Apr 16;8(4):e61077</RefSource>
<PMID Version="1">23613788</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2005 Feb;45(2):133-40</RefSource>
<PMID Version="1">15660820</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Res Notes. 2012 Mar 28;5:167</RefSource>
<PMID Version="1">22455501</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2015 Jul 12;15:267</RefSource>
<PMID Version="1">26164361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Expert Rev Gastroenterol Hepatol. 2008 Aug;2(4):553-62</RefSource>
<PMID Version="1">19072403</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Sep 13;8(9):e73472</RefSource>
<PMID Version="1">24058476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2012 Apr;52(4):880-92</RefSource>
<PMID Version="1">21981386</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Virol. 2015 Nov;72 :20-4</RefSource>
<PMID Version="1">26356987</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2010 Mar;82(3):454-8</RefSource>
<PMID Version="1">20207872</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:123-30</RefSource>
<PMID Version="1">21199523</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2006 Nov;13(11):715-24</RefSource>
<PMID Version="1">17052270</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Egypt J Immunol. 2014;21(1):13-26</RefSource>
<PMID Version="1">25204041</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2011 Jul;31(6):755-61</RefSource>
<PMID Version="1">21645206</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatol Int. 2016 Jan;10 (1):1-98</RefSource>
<PMID Version="1">26563120</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2008 Feb;48(2):286-94</RefSource>
<PMID Version="1">18028278</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2014 Jan;86(1):124-30</RefSource>
<PMID Version="1">24127328</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2005 Apr;75(4):513-21</RefSource>
<PMID Version="1">15714494</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Dec 12;9(12):e113821</RefSource>
<PMID Version="1">25503289</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2011 Jun;83(6):929-34</RefSource>
<PMID Version="1">21503902</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Infect Genet Evol. 2010 Dec;10(8):1242-6</RefSource>
<PMID Version="1">20727423</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2013 Oct;53(10 Pt 2):2459-66</RefSource>
<PMID Version="1">23621791</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2012 Dec;61(12):1744-53</RefSource>
<PMID Version="1">22267593</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Rep. 2015 Nov 16;5:16489</RefSource>
<PMID Version="1">26568165</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2014 Sep;61(3):688-9</RefSource>
<PMID Version="1">24976111</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Infect Dis. 2015 Jul;36:21-6</RefSource>
<PMID Version="1">25957815</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sex Transm Infect. 2008 Feb;84(1):37-41</RefSource>
<PMID Version="1">17804606</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2009 Feb 14;373(9663):582-92</RefSource>
<PMID Version="1">19217993</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anal Chem. 2015;87(10):5173-80</RefSource>
<PMID Version="1">25892477</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2016 Jan;63(1):284-306</RefSource>
<PMID Version="1">26566246</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Croat Med J. 2015 Jun;56(3):272-9</RefSource>
<PMID Version="1">26088852</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Microbiol. 2007 Nov 23;7:103</RefSource>
<PMID Version="1">18036224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Hepatol. 2011 Dec 27;3(12):292-9</RefSource>
<PMID Version="1">22216369</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2007 Jan;47(1):74-9</RefSource>
<PMID Version="1">17207233</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Biochem. 2013 Dec;46(18):1852-6</RefSource>
<PMID Version="1">24161476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dev Ctries. 2009 Jul 01;3(6):442-6</RefSource>
<PMID Version="1">19762957</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2000 Jul;32(1):129-34</RefSource>
<PMID Version="1">10869300</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Transl Med. 2012 Aug 28;10:176</RefSource>
<PMID Version="1">22929614</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Medicine (Baltimore). 2016 Apr;95(16):e3372</RefSource>
<PMID Version="1">27100421</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Indian J Med Res. 2006 Jan;123(1):37-42</RefSource>
<PMID Version="1">16567866</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatol Int. 2008 Sep;2(3):284-95</RefSource>
<PMID Version="1">19669256</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Virol J. 2013 Jan 18;10:25</RefSource>
<PMID Version="1">23332007</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2010;15(7):1029-34</RefSource>
<PMID Version="1">21041918</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2011 Jul;51(7):1532-40</RefSource>
<PMID Version="1">21251005</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2010 Apr;48(4):1105-11</RefSource>
<PMID Version="1">20107090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2011 Sep;83(9):1522-9</RefSource>
<PMID Version="1">21739441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vox Sang. 2003 May;84(4):287-91</RefSource>
<PMID Version="1">12757502</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol. 2009 Oct;83(19):9652-62</RefSource>
<PMID Version="1">19625407</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2011 May;49(5):1730-7</RefSource>
<PMID Version="1">21411575</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vox Sang. 2001 Apr;80(3):142-7</RefSource>
<PMID Version="1">11840974</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol. 2009 Aug;83(15):7649-58</RefSource>
<PMID Version="1">19458009</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Infect. 2013 Dec;19(12):E533-41</RefSource>
<PMID Version="1">23902574</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Phys Chem Chem Phys. 2013 Nov 7;15(41):18179-84</RefSource>
<PMID Version="1">24065125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfus Clin Biol. 2004 Feb;11(1):18-25</RefSource>
<PMID Version="1">14980545</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Gastroenterol Rep. 2012 Feb;14(1):37-46</RefSource>
<PMID Version="1">22105466</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Infect Dis. 2014 Dec;29:125-32</RefSource>
<PMID Version="1">25449246</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2002 Apr;36(4):543-6</RefSource>
<PMID Version="1">11943427</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Gastroenterol. 2007 Jan 7;13(1):82-90</RefSource>
<PMID Version="1">17206757</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2013 Oct;53(10 Pt 2):2477-88</RefSource>
<PMID Version="1">23521050</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2001 Jun;33(6):1527-32</RefSource>
<PMID Version="1">11391543</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2013 Oct;59(4):696-700</RefSource>
<PMID Version="1">23751755</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2010 May;138(5):1747-54</RefSource>
<PMID Version="1">20114048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol Methods. 2013 Dec;194(1-2):190-3</RefSource>
<PMID Version="1">24004823</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Lab Hematol. 2009 Dec;31(6):649-56</RefSource>
<PMID Version="1">18673399</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2012 Jul;57(1):167-85</RefSource>
<PMID Version="1">22436845</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2010 Aug;139(2):491-8</RefSource>
<PMID Version="1">20381492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Pediatr. 2011 Nov;7(4):358-60</RefSource>
<PMID Version="1">21874619</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2015 Jul;55(7):1803-11</RefSource>
<PMID Version="1">25648663</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anal Chim Acta. 2016 Feb 25;909:101-8</RefSource>
<PMID Version="1">26851090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vox Sang. 2014 Nov;107(4):324-32</RefSource>
<PMID Version="1">25040474</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2016 Apr;23 (4):286-93</RefSource>
<PMID Version="1">26663578</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Future Virol. 2013 Apr;8(4):371-380</RefSource>
<PMID Version="1">23662157</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Board Fam Med. 2015 Nov-Dec;28(6):822-37</RefSource>
<PMID Version="1">26546661</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepat Mon. 2014 May 01;14(5):e17263</RefSource>
<PMID Version="1">24829589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2003 Jun;43(6):788-98</RefSource>
<PMID Version="1">12757531</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2008 Sep;80(9):1565-9</RefSource>
<PMID Version="1">18649341</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2015 Mar;62(3):533-40</RefSource>
<PMID Version="1">25450717</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Res Notes. 2014 Dec 04;7:873</RefSource>
<PMID Version="1">25475050</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cleve Clin J Med. 2009 May;76 Suppl 3:S30-3</RefSource>
<PMID Version="1">19465707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dev Ctries. 2014 Aug 13;8(8):1013-5</RefSource>
<PMID Version="1">25116667</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Virol. 2014 Feb;59(2):89-93</RefSource>
<PMID Version="1">24355522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2003 Mar 15;101(6):2419-25</RefSource>
<PMID Version="1">12393691</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2016 Feb;88(2):260-7</RefSource>
<PMID Version="1">26241150</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vox Sang. 2015 Feb;108(2):113-22</RefSource>
<PMID Version="1">25234417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>S Afr Med J. 2011 Jun 27;101(7):477-80</RefSource>
<PMID Version="1">21920102</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Infect Genet Evol. 2013 Dec;20:103-10</RefSource>
<PMID Version="1">23978387</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2002 Jun;122(7):1756-62</RefSource>
<PMID Version="1">12055581</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Nov 12;8(11):e80346</RefSource>
<PMID Version="1">24265811</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol Methods. 2008 Aug;151(2):294-7</RefSource>
<PMID Version="1">18462816</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood Transfus. 2009 Jul;7(3):174-82</RefSource>
<PMID Version="1">19657480</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Exp Hepatol. 2014 Sep;4(3):226-40</RefSource>
<PMID Version="1">25755565</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2007 May;45(5):1187-92</RefSource>
<PMID Version="1">17465003</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2013 Jul;53(7):1405-15</RefSource>
<PMID Version="1">23362802</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chim Acta. 2010 Dec 14;411(23-24):1951-6</RefSource>
<PMID Version="1">20709042</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Jul 06;10(7):e0131912</RefSource>
<PMID Version="1">26148052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2008 Oct;49(4):652-7</RefSource>
<PMID Version="1">18715666</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Viral Immunol. 2016 Jan-Feb;29(1):40-8</RefSource>
<PMID Version="1">26565951</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2015 Apr;53(4):1156-63</RefSource>
<PMID Version="1">25631805</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Health Serv Res. 2013 Jan 31;13:37</RefSource>
<PMID Version="1">23368750</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2009 May;16(5):300-14</RefSource>
<PMID Version="1">19254351</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2010;15 Suppl 4:5-13</RefSource>
<PMID Version="1">21115576</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfus Med. 2010 Dec;20(6):409-13</RefSource>
<PMID Version="1">20573069</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2011 Mar;49(3):1154-6</RefSource>
<PMID Version="1">21177906</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2007 Jul;47(7):1197-205</RefSource>
<PMID Version="1">17581154</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Aug 10;30(37):5564-8</RefSource>
<PMID Version="1">22717331</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2015 Sep;87(9):1539-48</RefSource>
<PMID Version="1">25919572</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Semin Immunopathol. 2013 Jan;35(1):39-52</RefSource>
<PMID Version="1">22829332</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2009 Jun;49(6):1126-35</RefSource>
<PMID Version="1">19392770</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Exp Clin Immunogenet. 1995;12(3):171-81</RefSource>
<PMID Version="1">8534503</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Liver Dis. 2005 May;9(2):191-211, v</RefSource>
<PMID Version="1">15831268</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Jan 20;364(3):236-47</RefSource>
<PMID Version="1">21247314</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transfusion. 2015 Apr;55(4):890-7</RefSource>
<PMID Version="1">25363504</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2010 Mar;52(3):441-9</RefSource>
<PMID Version="1">20137824</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2010 May;51(5):1531-7</RefSource>
<PMID Version="1">20087968</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2009 Jun;49(6):1868-76</RefSource>
<PMID Version="1">19434719</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006513" MajorTopicYN="N">Hepatitis B e Antigens</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019694" MajorTopicYN="N">Hepatitis B, Chronic</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014775" MajorTopicYN="N">Virus Activation</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>10</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>5</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>9</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27625189</ArticleId>
<ArticleId IdType="pii">nrgastro.2016.138</ArticleId>
<ArticleId IdType="doi">10.1038/nrgastro.2016.138</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Ghana</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Angleterre de l'Est</li>
</region>
<settlement><li>Cambridge</li>
</settlement>
<orgName><li>Université de Cambridge</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Allain, Jean Pierre" sort="Allain, Jean Pierre" uniqKey="Allain J" first="Jean-Pierre" last="Allain">Jean-Pierre Allain</name>
</region>
</country>
<country name="Ghana"><noRegion><name sortKey="Opare Sem, Ohene" sort="Opare Sem, Ohene" uniqKey="Opare Sem O" first="Ohene" last="Opare-Sem">Ohene Opare-Sem</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A37 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000A37 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:27625189
   |texte=   Screening and diagnosis of HBV in low-income and middle-income countries.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:27625189" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SidaGhanaV1

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA au Ghana (serveur d'exploration)

Screening and diagnosis of HBV in low-income and middle-income countries.

Screening and diagnosis of HBV in low-income and middle-income countries.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki